Nilsine Partners’s Bristol-Myers Squibb BMY Stock Holding History

Nilsine Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$311K	Buy	4,977 +494	+11%	+$31.2K	0.02%	380
2026 Q2	$258K	Buy	4,483 +201	+5%	+$11.5K	0.02%	380
2026 Q1	$247K	Buy	+4,282	New	+$250K	0.02%	367
2025 Q3	–	Sell	-4,524	Closed	-$209K	–	402
2025 Q2	$209K	Sell	4,524 -1,227	-21%	-$60.2K	0.02%	367
2025 Q1	$351K	Sell	5,751 -568	-9%	-$33.1K	0.04%	280
2024 Q4	$357K	Buy	+6,319	New	+$353K	0.04%	294
2024 Q2	–	Sell	-9,739	Closed	-$528K	–	324
2024 Q1	$528K	Sell	9,739 -451	-4%	-$23K	0.07%	226
2023 Q4	$523K	Sell	10,190 -242	-2%	-$12.7K	0.08%	217
2023 Q3	$605K	Sell	10,432 -548	-5%	-$33.6K	0.09%	202
2023 Q2	$702K	Buy	10,980 +418	+4%	+$28K	0.1%	193
2023 Q1	$732K	Buy	+10,562	New	+$745K	0.11%	188

Other funds holding BMY

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 26.62% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Nilsine Partners's BMY Position: Q3 2026 in Review

Nilsine Partners increased its Bristol-Myers Squibb (BMY) stake by 11% in Q3 2026, buying an estimated $31.2K and bringing the position to 4,977 shares worth $311K. The position accounts for 0.02% of the portfolio, ranked #380.

Nilsine Partners first reported a position in BMY in Q1 2023 and has held it in 11 quarters since. The position peaked at $732K in Q1 2023. 1,763 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

Nilsine Partners held 4,977 shares of Bristol-Myers Squibb worth $311K as of Q3 2026.
Nilsine Partners bought 494 Bristol-Myers Squibb shares in Q3 2026, an estimated $31.2K.
Bristol-Myers Squibb made up 0.02% of Nilsine Partners's portfolio in Q3 2026, its #380 holding.
Nilsine Partners first reported a position in Bristol-Myers Squibb in Q1 2023 and has held it in 11 quarters since.
Nilsine Partners's Bristol-Myers Squibb position peaked at $732K in Q1 2023.
1,763 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Nilsine Partners's 13F filing for Q3 2026, filed 2 Nov 2026.